Diurnal Share Discussion Threads

[basem1] 02/12/2020 11:32

15000 at 49.6 for me Even if we haven't we are only 2-3p away from the bottom

[aimmafia] 02/12/2020 11:30

We have to be close to the bottom. It's rediculously under valued here

[jusjusjus] 02/12/2020 11:28

waiting to see if the mm's have sucked buyers in again on RG selling (the zig-zags on the chart from below 60p), needs to break more before dipping my toe in!

[aimmafia] 02/12/2020 11:21

Just taken another 20k that's me done for today

[aimmafia] 02/12/2020 11:13

I have added around 10k today

[aimmafia] 02/12/2020 11:12

Ticking up on hardly anything. This is the perfect time to load up if you're a new investor

[aimmafia] 02/12/2020 10:39

Moving on fresh air now. Wouldn't surprise me if we have a 10% - 20% up day soon

[tburns] 02/12/2020 10:38

I think the inevitable re-rate is starting today.

[trotterstrading] 02/12/2020 10:22

Looks that way, or it's reached a floor price for the seller.. either way it makes current level an excellent entry / top up price!!

[basem1] 02/12/2020 10:12

Another false dawn or is our seller cleared ? Time will tell

[cyberbub] 01/12/2020 23:05

I agree that Diurnal could use some of the recent cash raising to take a secondary US listing, just OTC/ADRs initially and then as newsflow/cashflow start rising they could go for a full listing? The Americans know how to properly value pharma companies!

[royalalbert] 01/12/2020 20:00

Nothing until you let it go.

[weatherman] 01/12/2020 18:10

What happens when you hold a beach ball under water ?

[best1467] 01/12/2020 17:16

Back to DNL the drop continues taking valuation out of the picture the chart is suggesting 44p which is crazy looking at the fundamentals and achievements achieved recently.
I will continue to add to what is now becoming a extremely large holding but the value just keeps drawing me back in the same thing was in place for 18 months when it lingered in the high 20 p to mid 30 p range now we have FDA approval FDA guidance for a shorter route to market for Ditest and Chronocort getting EMA confirmation of the new submission data for Chronocort and we can now buy at 48 p amazing

[best1467] 01/12/2020 17:05

I’m flabbergasted in fact I nearly choked on my coffee to compare DNL to INM suggests you have absolutely Zero understand of both companies this comment may sound harsh but to suggest similar companies is Incomprehensible

[dandu69] 01/12/2020 14:19

Thanks for all the input guys, this novice investor really appreciates all the views.

[lovewinshatelosses] 01/12/2020 14:02

Good luck with IMM, dandu. I am in the same boat as others who are fearful of that one - but if they do manage to turn it around this time, of course it will likely offer a very nice upside for pre-results holders. Very different kettle of fish to DNL though.
Meanwhile, the annoying drift here continues. Looks like 45p was not unrealistic after all. I should have a few more pennies to invest at that price next week - assuming it does happen of course. Extraordinary really.

[l0ngterm] 01/12/2020 14:02

Overall comparing from a holistic perspective the U.K. to any US exchange is never going to be realistic. Looked at broker targets for Eton (take with a pinch of salt). And it looks like targets are 100% plus. The bigger question might be why does ETON not just takeover DNL?

[nobbygnome] 01/12/2020 13:54

DNL is nothing like IMM; chalk and cheese comes to mind!

[74tom] 01/12/2020 13:52

And still Griffiths sells... The problem here, along with many other AIM small caps is lack of volume. One big holder decides to dump and the price gets taken to the cleaners. Comparing DNL with ETON is very interesting, in that they are two similar size small cap pharma's but trade on different exchanges.

In the last 100 trading days starting on 13th July, DNL has total share volume of 49.5m, multiplying this by each days closing price we can estimate that around £28.2m has flowed through in this period.

In the same period ETON has traded 46.6m shares, for a total value of around $348m (£261m).

ETON started the 100 day period at $5.62 per share with 21m shares in issue, so had a market cap of $118m (£88m).

DNL started the 100 day period at 30p per share with 122m shares in issue, so had a market cap of £36m.

So both shares have been in a rising trend with positive news & both have also raised cash in the period, with ETON placing at $7 to raise $19m. Yet comparing share turnover vs market cap 100 days ago, ETON has traded nearly 3 x it's cap, whilst DNL has only traded 80%. This is the issue.

Personally, whilst I'll keep an eye on DNL for bounce trade, I think the best way to benefit from Alkindi is to buy ETON shares. They have a pipeline of 8 other drugs & forecast FY22 sales of $74m... if they execute on that then their market cap could be $1b+. I also think there is a good chance they will in licence Chronocort too, particularly if they nail the Alkindi roll out.

DNL meanwhile will continue to be handicapped by the lack of interest in UK small cap pharma, they would do far better moving to the US / anywhere other than AIM.

[trotterstrading] 01/12/2020 11:57

IMM is a one trick pony - a binary bet and Lupuzor has already failed a P3 trial, Lupus is notoriously difficult to treat. DNL a far safer bet IMHO

[dandu69] 01/12/2020 11:41

I know I`m a novice but I sold half my holding here yesterday and put it into IMM, very similar company. No doubt people on this board will be aware of it but could be worth exploring if desired.

[bad gateway] 01/12/2020 11:38

Diredurnal.

[dandu69] 01/12/2020 10:50

That`s fine mafia, from someone who considers themselves to be a novice I take that as a compliment. Look forward to reading and learning from your professional posts in the future.